

Jacques-Eric Gottenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6926681/publications.pdf>

Version: 2024-02-01

108
papers

14,536
citations

44069

48
h-index

30087

103
g-index

110
all docs

110
docs citations

110
times ranked

11857
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial" by de Wolff et al. Annals of the Rheumatic Diseases, 2023, 82, e149-e149.	0.9	5
2	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
3	Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology, 2022, 61, 953-962.	1.9	15
4	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatology, The, 2022, 4, e8-e11.	3.9	29
5	Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. Lancet Rheumatology, The, 2022, 4, e13-e16.	3.9	40
6	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases, 2022, 81, 184-192.	0.9	40
7	Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine, 2022, 89, 105310.	1.6	2
8	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.8	3
9	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.9	27
10	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
11	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.9	153
12	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. European Journal of Internal Medicine, 2021, 85, 41-49.	2.2	11
13	Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 339-348.	0.9	63
14	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. Rheumatology, 2021, 60, 1364-1375.	1.9	26
15	Response to: "Correspondence on "Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial" by Wang et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-219882.	0.9	8
16	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
17	Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundamental and Clinical Pharmacology, 2021, 35, 1090-1099.	1.9	5
18	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatology International, 2021, 41, 1593-1600.	3.0	13

#	ARTICLE	IF	CITATIONS
19	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology</i> , The, 2021, 3, e553-e562.	3.9	31
20	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-220549.	0.9	18
21	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 329-338.	0.9	61
22	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
23	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.8	0
24	Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial. <i>Rheumatology</i> , 2020, 59, 107-111.	1.9	50
25	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
26	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	1.9	54
27	Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNF. <i>Clinical Rheumatology</i> , 2020, 39, 2553-2562.	2.2	2
28	Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020, 22, 39.	3.5	8
29	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
30	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.8	2
31	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 315.	7.4	210
32	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	3.8	53
33	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 860-862.	0.9	14
34	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2019, 364, l67.	2.3	76
35	Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 1153.	4.8	19
36	The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials. <i>Autoimmunity Reviews</i> , 2019, 18, 576-582.	5.8	31

#	ARTICLE	IF	CITATIONS
37	The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding. <i>Cell Death and Disease</i> , 2019, 10, 190.	6.3	33
38	AB0458â€¦A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÄ¶GRENâ€™S SYNDROME (PSS). , 2019, , .		1
39	SP0190â€¦2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÄ¶GRENâ€™S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
40	Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNF± treatment. <i>Joint Bone Spine</i> , 2019, 86, 401-403.	1.6	8
41	Sicca/SjÄ¶gren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.8	19
42	Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. <i>Rheumatology</i> , 2018, 57, 538-547.	1.9	43
43	Efficacy of Epratuzumab, an Antiâ€œCD</sc>22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated SjÄ¶gren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	5.6	49
44	Efficacy and safety of rituximab for systemic lupus erythematosusâ€œassociated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
45	Role of the IL-12/IL-35 balance in patients with SjÄ¶gren syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 258-268.e5.	2.9	34
46	Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 122.	3.5	7
47	How immunological profile drives clinical phenotype of primary SjÄ¶gren's syndrome at diagnosis: analysis of 10,500 patients (SjÄ¶gren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
48	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orenica in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	1.9	10
49	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.9	150
50	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
51	Influence of geolocation and ethnicity on the phenotypic expression of primary SjÄ¶gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjÄ¶gren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
52	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
53	History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort. <i>European Journal of Internal Medicine</i> , 2017, 46, e13-e14.	2.2	1
54	Brief Report: Defective Early B Cell Tolerance Checkpoints in SjÄ¶gren's Syndrome Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2203-2208.	5.6	40

#	ARTICLE	IF	CITATIONS
55	Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhusus: an open-label study of 15 patients. <i>RMD Open</i> , 2017, 3, e000555.	3.8	20
56	History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs. <i>Journal of Clinical Medicine</i> , 2017, 6, 92.	2.4	6
57	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1945-1950.	0.9	57
58	Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. <i>Scientific Reports</i> , 2016, 6, 18421.	3.3	51
59	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	1.9	22
60	Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases. <i>Drugs - Real World Outcomes</i> , 2016, 3, 393-399.	1.6	9
61	Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1172.	7.4	160
62	Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1346-1352.	5.6	102
63	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
64	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	3.0	118
65	Association of Anti- <i>Porphyromonas gingivalis</i> Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1729-1737.	5.6	61
66	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015, 10, e0133907.	2.5	19
67	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
68	B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. <i>Journal of Autoimmunity</i> , 2015, 56, 1-11.	6.5	88
69	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015, 54, 1699-1708.	1.9	49
70	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015, 54, 2230-2238.	1.9	220
71	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
72	Evaluation of Serum Interleukin-6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 905-912.	3.4	55

#	ARTICLE	IF	CITATIONS
73	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 249.	7.4	241
74	Outcome measures for primary Sjögren's syndrome: A comprehensive review. Journal of Autoimmunity, 2014, 51, 51-56.	6.5	77
75	Classification criteria and treatment modalities in primary Sjögren's syndrome. Expert Review of Clinical Immunology, 2014, 10, 543-551.	3.0	6
76	Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjögren's syndrome. Journal of Autoimmunity, 2014, 51, 57-66.	6.5	123
77	When biologics should be used in systemic lupus erythematosus?. Presse Medicale, 2014, 43, e181-e185.	1.9	5
78	Treatment of Primary Sjögren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 160, 233-242.	3.9	325
79	Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue. Annals of the Rheumatic Diseases, 2013, 72, 476-478.	0.9	90
80	Critères diagnostiques du syndrome de Gougerot-Sjögren. Revue Du Rhumatisme Monographies, 2013, 80, 20-25.	0.0	3
81	Role of Fms-like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary Sjögren's Syndrome. Arthritis and Rheumatism, 2013, 65, 3218-3227.	6.7	46
82	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Annals of the Rheumatic Diseases, 2013, 72, 1026-1031.	0.9	193
83	B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Research and Therapy, 2013, 15, R168.	3.5	115
84	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. PLoS ONE, 2013, 8, e59868.	2.5	147
85	Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ORENCIA and Rheumatoid Arthritis registry. Annals of the Rheumatic Diseases, 2012, 71, 1815-1819.	0.9	117
86	Primary Sjögren's Syndrome: Time for Prospective Cohorts. Current Pharmaceutical Biotechnology, 2012, 13, 2022-2025.	1.6	4
87	Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Annals of the Rheumatic Diseases, 2012, 71, 1243-1248.	0.9	74
88	Outcome measures for primary Sjögren's syndrome. Journal of Autoimmunity, 2012, 39, 97-102.	6.5	46
89	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2011, 70, 968-972.	0.9	383
90	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 909-920.	0.9	394

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. <i>Rheumatology</i> , 2011, 50, 2283-2289.	1.9	56
92	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. <i>Rheumatology</i> , 2011, 50, 222-229.	1.9	159
93	Pathogenesis of Sjögren's syndrome and therapeutic consequences. <i>Current Opinion in Rheumatology</i> , 2010, 22, 471-477.	4.3	78
94	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
95	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2625-2632.	6.7	266
96	Syndrome de Sjögren primitif: critères diagnostiques et de suivi. <i>Revue Du Rhumatisme Monographies</i> , 2010, 77, 108-113.	0.0	0
97	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1103-1109.	0.9	734
98	B cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. <i>European Journal of Immunology</i> , 2009, 39, 1271-1279.	2.9	35
99	The CGGGC insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2009, 60, 1991-1997.	6.7	104
100	Syndrome de Sjögren primitif: avancées physiopathologiques, cliniques et thérapeutiques. <i>Revue Du Rhumatisme (Édition Française)</i> , 2009, 76, 944-948.	0.0	0
101	Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type I IFN-dependent and -independent pathways. <i>European Journal of Immunology</i> , 2008, 38, 1058-1064.	2.9	141
102	Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 700-702.	0.9	159
103	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 351-357.	0.9	261
104	Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 790-797.	0.9	77
105	BAFF synthesis by rheumatoid synoviocytes is positively controlled by $\alpha 5 \beta 1$ integrin stimulation and is negatively regulated by tumor necrosis factor α and toll-like receptor ligands. <i>Arthritis and Rheumatism</i> , 2007, 56, 3202-3214.	6.7	35
106	No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2006, 8, R30.	3.5	38
107	Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2770-2775.	7.1	542
108	In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. <i>Arthritis and Rheumatism</i> , 2003, 48, 2240-2245.	6.7	150